drugset
drugset / Trial / NCT00310635

Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age

NCT00310635 ↗

Phase 4 Completed 241 enrolled Novartis Novartis Vaccines · collab
Non-randomizedParallel-groupOpen-labelPrevention

Summary

Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age

Timeline

Start
2005-06
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Menjugate Vaccine — —

Indications

meningococcal infection